ImmunityBio, Inc. statistics & valuation
Net margin-310.2%
FCF margin-272.6%
Return on capital-58.2%
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Net margin (%)Gross margin (%)Operating margin (%)Return on equity (%)Shares outstandingNet debt ($)Share buybacks ($)Return on assets (%)Free cash flow margin (%)Debt / equity (×)EPS ($) Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|
| Operating margin | -226.0% | -2334.2% | -58239.5% | -146374.2% | -35361.9% | -36509.1% | -7095.9% | -209338.3% | -220266.7% | -282954.5% |
| Net margin | -310.2% | -2804.8% | -93761.4% | -173569.6% | -37129.6% | -36669.6% | -7165.2% | -204736.2% | -214273.3% | -274565.9% |
| FCF margin | -272.6% | -2700.1% | -63881.2% | -173196.2% | -32974.5% | -28660.0% | -7102.5% | -162729.8% | -185766.7% | -102620.5% |
| Return on assets | -70.0% | -108.0% | -115.6% | -115.0% | -74.0% | -100.2% | -110.2% | -52.9% | -38.5% | -38.1% |
| Return on equity | 70.2% | 84.6% | 99.4% | 92.6% | 142.2% | 185.2% | -130.7% | -65.9% | -44.1% | -41.2% |
| Current ratio | 5.10 | 3.36 | 5.05 | 0.28 | 0.91 | 1.64 | 4.82 | 3.26 | 6.35 | 16.34 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.
Stocktoria
